News

Article

AJMC® in the Press, April 4, 2025

Key Takeaways

  • Medicare Advantage growth in rural areas from 2008 to 2019 improved hospital sustainability, highlighting policy impacts on healthcare infrastructure.
  • Hepatitis B vaccine choices are evolving, informed by clinical data and CDC recommendations, emphasizing the importance of evidence-based vaccination strategies.
SHOW MORE

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article from Michigan Advance referenced a study published in the November 2023 issue of The American Journal of Managed Care® (AJMC®). The study, “Medicare Advantage in Rural Areas: Implications for Hospital Sustainability,” found that Medicare Advantage penetration rose between 2008 and 2019, associated with an increase in hospital sustainability.

An article by Very Well Health referenced an article published in a 2023 supplement to AJMC, titled “Evolving Considerations for Choice of Hepatitis B Vaccine.” The overview provided considerations for the hepatitis B vaccine based on the clinical data around the vaccines and CDC recommendations.

An article from AI in Healthcare referenced a video interview published on AJMC.com, the website of AJMC. The video interview, “AI Is Changing the Landscape of Cardiovascular Care,” focused on how artificial intelligence can help both clinicians and health systems in their abilities to screen for cardiorenalmetabolic disease as well as distinguish between them.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Gordon Crofoot, MD, PA
David Awad, PharmD, BCOP
Merrill H. Stewart, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo